GleamWall
中文EN

IRWD IRONWOOD PHARMACEUTICALS INC

Pharmaceutical Preparations · Nasdaq · SEC CIK 1446847 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.1%
TTM net income YoY424.1%
TTM EPS YoY400.0%
Revenue 3-yr CAGR-2.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin62.9%
Net margin37.4%
FCF margin—
EBITDA margin63.2%

Returns

ROE—
ROA43.6%
ROIC (approx.)—
Asset turnover1.17x

Leverage & solvency

Liabilities / assets133.4%
Debt / equity—
Current ratio6.51x
Interest coverage8.28x

Cash quality & payout

Operating cash flow / net income1.37x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$296.15M$351.41M
R&D expense$95.14M$111.42M
SG&A expense$82.26M$144.27M
Operating income$98.50M$93.12M
Interest expense$32.75M$33.03M
Pretax income$70.03M$65.20M
Income tax$46.01M$64.32M
Net income$24.02M$880,000
EBITDA$99.60M$94.32M
EPS (basic)0.150.01
EPS (diluted)0.150.01
Weighted avg. shares (diluted)162.98M160.08M
Balance sheet
Cash & equivalents$215.46M$88.56M
Receivables$46.74M$81.89M
Current assets$274.18M$182.37M
PP&E, net$3.41M$4.50M
Intangibles$2.04M$2.86M
Total assets$396.90M$350.91M
Current liabilities$242.22M$38.85M
Long-term debt—$198.99M
Total debt—$198.99M
Total liabilities$658.74M$652.24M
Shareholders' equity-$261.83M-$301.33M
Net debt—$110.43M
Shares outstanding163.06M160.21M
Cash flow statement
Operating cash flow$127.04M$103.55M
Capital expenditure$34,000$142,000
Free cash flow$127.01M$103.41M
Investing cash flow-$34,000-$142,000
Financing cash flow$216,000-$106.97M
Depreciation & amortization$1.10M$1.20M
Stock-based compensation$17.25M$29.85M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.